Noxopharm Ltd has released a press release.
SOF-SKN passes required in vitro safety tests
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- December 2024 Quarterly Activities Report and Appendix 4C
- Additional convertible note for long-term shareholder
- September 2024 Quarterly Activities report and Appendix 4C
- New funding from sophisticated investors
- Advanced funding secured ahead of R&D rebate
Later from Noxopharm
- Appendix 4D and FY2025 Half Year Financial Report
- March 2025 Quarterly Activities Report and Appendix 4C
- New funds from Nyrada share sales
- Green light for HERACLES clinical trial
- Promising Sofra results from overseas company
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm